Ghent University Academic Bibliography

Advanced

M2-based influenza vaccines : recent advances and clinical potential

Annasaheb Kolpe UGent, Bert Schepens UGent, Walter Fiers UGent and Xavier Saelens UGent (2017) EXPERT REVIEW OF VACCINES. 16(2). p.123-136
abstract
Introduction: Current influenza vaccines can prevent disease caused by influenza viruses but require annual administration and almost yearly reformulation. An attractive alternative approach would be to use a vaccine that provides broad and, ideally, lifelong protection against all influenza A and B virus strains. The extracellular domain of matrix protein 2 (M2e) of influenza A viruses is conserved and thus fits well in such a broadly protective vaccine.Areas covered: Recent advances in M2e vaccine design, the mode of action of M2e-based immunity and clinical progress of M2-based influenza vaccines. Expert commentary: Many M2e vaccine have been successfully tested for efficacy against a panel of divergent influenza viruses in animal models. More recently, clinical studies have been conducted with M2e vaccine candidates, which demonstrated their safety and immunogenicity in humans. Efficacy studies in humans are still needed to provide evidence that an M2e-based vaccine can protect against human influenza.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
Clinical trial, influenza A virus, M2e, matrix protein 2, broadly protective vaccines, broadly protecting antibodies, VIRUS-LIKE PARTICLES, IMPROVED CROSS-PROTECTION, DEPENDENT CELLULAR CYTOTOXICITY, M2 EXTRACELLULAR DOMAINS, A-VIRUS, MATRIX PROTEIN-2, MONOCLONAL-ANTIBODY, FUSION PROTEIN, IMMUNE-RESPONSES, UNIVERSAL VACCINE
journal title
EXPERT REVIEW OF VACCINES
Expert Rev. Vaccines
volume
16
issue
2
pages
123 - 136
Web of Science type
Review
Web of Science id
000392988900005
ISSN
1476-0584
DOI
10.1080/14760584.2017.1240041
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
8512291
handle
http://hdl.handle.net/1854/LU-8512291
date created
2017-03-02 14:17:57
date last changed
2017-05-29 08:57:55
@article{8512291,
  abstract     = {Introduction: Current influenza vaccines can prevent disease caused by influenza viruses but require annual administration and almost yearly reformulation. An attractive alternative approach would be to use a vaccine that provides broad and, ideally, lifelong protection against all influenza A and B virus strains. The extracellular domain of matrix protein 2 (M2e) of influenza A viruses is conserved and thus fits well in such a broadly protective vaccine.Areas covered: Recent advances in M2e vaccine design, the mode of action of M2e-based immunity and clinical progress of M2-based influenza vaccines.
Expert commentary: Many M2e vaccine have been successfully tested for efficacy against a panel of divergent influenza viruses in animal models. More recently, clinical studies have been conducted with M2e vaccine candidates, which demonstrated their safety and immunogenicity in humans. Efficacy studies in humans are still needed to provide evidence that an M2e-based vaccine can protect against human influenza.},
  author       = {Kolpe, Annasaheb and Schepens, Bert and Fiers, Walter and Saelens, Xavier},
  issn         = {1476-0584},
  journal      = {EXPERT REVIEW OF VACCINES},
  keyword      = {Clinical trial,influenza A virus,M2e,matrix protein 2,broadly protective vaccines,broadly protecting antibodies,VIRUS-LIKE PARTICLES,IMPROVED CROSS-PROTECTION,DEPENDENT CELLULAR CYTOTOXICITY,M2 EXTRACELLULAR DOMAINS,A-VIRUS,MATRIX PROTEIN-2,MONOCLONAL-ANTIBODY,FUSION PROTEIN,IMMUNE-RESPONSES,UNIVERSAL VACCINE},
  language     = {eng},
  number       = {2},
  pages        = {123--136},
  title        = {M2-based influenza vaccines : recent advances and clinical potential},
  url          = {http://dx.doi.org/10.1080/14760584.2017.1240041},
  volume       = {16},
  year         = {2017},
}

Chicago
Kolpe, Annasaheb, Bert Schepens, Walter Fiers, and Xavier Saelens. 2017. “M2-based Influenza Vaccines : Recent Advances and Clinical Potential.” Expert Review of Vaccines 16 (2): 123–136.
APA
Kolpe, A., Schepens, B., Fiers, W., & Saelens, X. (2017). M2-based influenza vaccines : recent advances and clinical potential. EXPERT REVIEW OF VACCINES, 16(2), 123–136.
Vancouver
1.
Kolpe A, Schepens B, Fiers W, Saelens X. M2-based influenza vaccines : recent advances and clinical potential. EXPERT REVIEW OF VACCINES. 2017;16(2):123–36.
MLA
Kolpe, Annasaheb, Bert Schepens, Walter Fiers, et al. “M2-based Influenza Vaccines : Recent Advances and Clinical Potential.” EXPERT REVIEW OF VACCINES 16.2 (2017): 123–136. Print.